Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Can Lower Doses of EGFR Inhibitor Therapy Still be Effective?
Please Note: While this is Still Excellent Background Info, New Treatments and Procedures Have Emerged Since this Original Post
Author
Howard (Jack) West, MD

One nagging question that people often ask about, or at least worry about, is whether they are compromising their ability to benefit from an EGFR tyrosine kinase inhibitor (TKI) like Tarceva (erlotinib) or Iressa (gefitinib) if they need to cut down on the dose because of problems with side effects. Anecdotally, I think just about every clinical oncologist believes that is absolutely not the case, based on the fact that many of our patients who have very dramatic and prolonged responses to EGFR inhibitors have also required one or more dose reductions and continue to do very well on a lower dose than the starting dose of Tarceva at 150 mg/day or Iressa at 250 mg/day. We also know from lab-based work that cancer cells with an EGFR mutation are about ten times as sensitive to the effects of EGFR TKIs than cancer cells without an EGFR mutation. This suggests that patients who have an NSCLC tumor with an EGFR mutation may require a lower than standard dose to still receive the benefits. At this year's ASCO meeting, Inoue and colleagues will present a retrospective analysis of outcomes based on dose for patients on their study of standard chemo vs. Iressa for patients with an EGFR mutation detected before starting first line therapy. kobayashi-nej002-trial (click on image to enlarge)

The retrospective analysis compares the results of 52 (46%) of patients who continued at full dose Iressa with the 62 (54% (!!)) who had a dose-reduction of Iressa, generally switching to once every two day treatment (because there are no lower dose tablets of gefitinib than 250 mg). The analysis showed no significant difference at all in outcomes, and even a numerically longer median progression-free survival of 351 days vs. 301 days, and median overall survival of 928 days vs. 852 days, for the lower dose vs. full dose recipients, respectively. This doesn't mean that lower dosing is a superior strategy (these are not close to statistically significant differences, and the groups aren't huge), but it should allay anyone's fears that the people who need to reduce dose of their EGFR inhibitor due to challenging side effects are compromising their treatment -- at least for patients who have tumors with an EGFR mutation.

Next Previous link

Previous PostNext Post

Related Content

Article
Las biopsias líquidas están revolucionando la forma en que combatimos el cáncer, ofreciendo un futuro donde la detección y el tratamiento son más rápidos, precisos y menos invasivos.
Image
Videoteca de Cáncer de Pulmon - 2025
Video
Como parte de la Videoteca de Cáncer de Pulmón en Español 2025, oncólogos expertos discuten las opciones de tratamiento y la información más emergente en cáncer de pulmón. El Dr. Raez aborda la terapia para cánceres de pulmón EGFR y ALK, además de analizar otros tres temas de actualidad. La Dra. Viola y la Dra. Riaño también contribuyen a esta videoteca, cada una presentando tres temas relevantes sobre el cáncer de pulmón.
Article
The journey to conquer lung cancer is paved with scientific discovery, and the identification of the EGFR and ALK genes as crucial players marks a significant milestone. Unraveling how mutations in these seemingly small segments of our DNA can unleash the destructive force of cancer has opened up exciting new therapeutic avenues. This exploration delves into the cutting-edge world of EGFR and ALK-targeted therapies, highlighting the progress made and the ongoing quest for even more effective and personalized strategies to combat this formidable disease.

Recent Comments

JOIN THE CONVERSATION
HOW I GOT CURED OF MY PARKINSON DISEASE
By NellyArmstrong on
HOW I GOT CURED POOF MY DISEASE
By NellyArmstrong on
Hi there, thank you for…
By kidjaialai on
Thanks for sharing—amazing…
By MakaylaLove on